Business context and reporting period
Genmab A/S filed this Form 6-K as a foreign private issuer for October 2026. The report is dated October 2, 2026, and identifies the company’s principal executive offices in Valby, Denmark.
Financial results and key metrics
The filing text provided contains no revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics.
Material changes and outlook
The exhibit index lists a company announcement dated October 2, 2026, titled “Major Shareholder Update,” but the announcement’s contents are not included. No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided text.
Other filing information
The 6-K states that it is incorporated by reference into specified Genmab Form S-8 registration statements, to the extent not superseded by later filings or reports. It was signed by Anthony Pagano, Executive Vice President and Chief Financial Officer.
Investor verification points
- Review Exhibit 99.1 for the details and significance of the major shareholder update.
- Consult Genmab’s relevant financial filings for current financial results, liquidity, debt, and outlook; this 6-K text provides no such information.